186 related articles for article (PubMed ID: 22641288)
1. [Dendritic cell-based therapeutic vaccination for acute myeloid leukemia].
Anguille S; Van Tendeloo V; Berneman Z
Bull Cancer; 2012 Jun; 99(6):635-42. PubMed ID: 22641288
[TBL] [Abstract][Full Text] [Related]
2. Leukemia-derived dendritic cells: towards clinical vaccination protocols in acute myeloid leukemia.
Houtenbos I; Westers TM; Ossenkoppele GJ; van de Loosdrecht AA
Haematologica; 2006 Mar; 91(3):348-55. PubMed ID: 16531258
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cell vaccination in acute myeloid leukemia.
Anguille S; Willemen Y; Lion E; Smits EL; Berneman ZN
Cytotherapy; 2012 Jul; 14(6):647-56. PubMed ID: 22686130
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy.
Acheampong DO; Adokoh CK; Asante DB; Asiamah EA; Barnie PA; Bonsu DOM; Kyei F
Biomed Pharmacother; 2018 Jan; 97():225-232. PubMed ID: 29091870
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of clinical dendritic cell vaccination in acute myeloid leukemia.
Houtenbos I; Westers TM; Ossenkoppele GJ; van de Loosdrecht AA
Immunobiology; 2006; 211(6-8):677-85. PubMed ID: 16920506
[TBL] [Abstract][Full Text] [Related]
6. Peptide vaccines for patients with acute myeloid leukemia.
Schmitt M; Casalegno-Garduño R; Xu X; Schmitt A
Expert Rev Vaccines; 2009 Oct; 8(10):1415-25. PubMed ID: 19803762
[TBL] [Abstract][Full Text] [Related]
7. Efficient monocyte-derived dendritic cell generation in patients with acute myeloid leukemia after chemotherapy treatment: application to active immunotherapy.
Royer PJ; Bougras G; Ebstein F; Leveque L; Tanguy-Royer S; Simon T; Juge-Morineau N; Chevallier P; Harousseau JL; Gregoire M
Exp Hematol; 2008 Mar; 36(3):329-39. PubMed ID: 18207305
[TBL] [Abstract][Full Text] [Related]
8. Profiles of activation, differentiation-markers, or β-integrins on T cells contribute to predict T cells' antileukemic responses after stimulation with leukemia-derived dendritic cells.
Vogt V; Schick J; Ansprenger C; Braeu M; Kroell T; Kraemer D; Köhne CH; Hausmann A; Buhmann R; Tischer J; Schmetzer H
J Immunother; 2014; 37(6):331-47. PubMed ID: 24911794
[TBL] [Abstract][Full Text] [Related]
9. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
Grabrucker C; Liepert A; Dreyig J; Kremser A; Kroell T; Freudenreich M; Schmid C; Schweiger C; Tischer J; Kolb HJ; Schmetzer H
J Immunother; 2010 Jun; 33(5):523-37. PubMed ID: 20463595
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cell-based immunotherapy in acute and chronic myeloid leukaemia.
Westers TM; Ossenkoppele GJ; van de Loosdrecht AA
Biomed Pharmacother; 2007 Jul; 61(6):306-14. PubMed ID: 17368821
[TBL] [Abstract][Full Text] [Related]
11. Procedures for the expansion of CD14(+) precursors from acute myeloid leukemic cells to facilitate dendritic cell-based immunotherapy.
van den Ancker W; Wijnands PG; Ruben JM; Westers TM; Punt B; Bachas C; Ravenshorst N; van Wetering S; Kruisbeek AM; Bontkes HJ; Ossenkoppele GJ; van de Loosdrecht AA; de Gruijl TD
Immunotherapy; 2013 Nov; 5(11):1183-90. PubMed ID: 24188673
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts.
Li L; Giannopoulos K; Reinhardt P; Tabarkiewicz J; Schmitt A; Greiner J; Rolinski J; Hus I; Dmoszynska A; Wiesneth M; Schmitt M
Int J Oncol; 2006 Apr; 28(4):855-61. PubMed ID: 16525634
[TBL] [Abstract][Full Text] [Related]
13. Effects of dendritic cell-activated and cytokine-induced killer cell therapy on 22 children with acute myeloid leukemia after chemotherapy.
Bai Y; Zheng JE; Wang N; Cai HH; Zhai LN; Wu YH; Wang F; Jin RM; Zhou DF
J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):689-693. PubMed ID: 26489623
[TBL] [Abstract][Full Text] [Related]
14. Employing the immunological synapse in AML: development of leukemic dendritic cells for active specific immunization.
Houtenbos I; Westers TM; Ossenkoppele GJ; van de Loosdrecht AA
Immunobiology; 2005; 210(2-4):249-57. PubMed ID: 16164032
[TBL] [Abstract][Full Text] [Related]
15. Targeting the acute myeloid leukemic stem cell compartment by enhancing tumor cell-based vaccines.
Ruben JM; Visser LL; Bontkes HJ; Westers TM; Ossenkoppele GJ; de Gruijl TD; van de Loosdrecht AA
Immunotherapy; 2013 Aug; 5(8):859-68. PubMed ID: 23902555
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell-based immunotherapy in myeloid leukaemia: translating fundamental mechanisms into clinical applications.
van de Loosdrecht AA; van den Ancker W; Houtenbos I; Ossenkoppele GJ; Westers TM
Handb Exp Pharmacol; 2009; (188):319-48. PubMed ID: 19031033
[TBL] [Abstract][Full Text] [Related]
17. A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia.
van de Loosdrecht AA; van Wetering S; Santegoets SJAM; Singh SK; Eeltink CM; den Hartog Y; Koppes M; Kaspers J; Ossenkoppele GJ; Kruisbeek AM; de Gruijl TD
Cancer Immunol Immunother; 2018 Oct; 67(10):1505-1518. PubMed ID: 30039426
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapeutic strategies for relapse control in acute myeloid leukemia.
Martner A; Thorén FB; Aurelius J; Hellstrand K
Blood Rev; 2013 Sep; 27(5):209-16. PubMed ID: 23871358
[TBL] [Abstract][Full Text] [Related]
19. Current progress in the development of a cell-based vaccine for the immunotherapy of acute myeloid leukemia.
Klammer M; Roddie PH
Expert Rev Vaccines; 2006 Apr; 5(2):211-22. PubMed ID: 16608421
[TBL] [Abstract][Full Text] [Related]
20. Activation of autologous leukemia-specific T cells in acute myeloid leukemia: monocyte-derived dendritic cells cocultured with leukemic blasts compared with leukemia-derived dendritic cells.
Draube A; Beyer M; Wolf J
Eur J Haematol; 2008 Oct; 81(4):281-8. PubMed ID: 18573171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
